B vitamin therapy for homocysteine: renal function and vitamin B12 determine cardiovascular outcomes

References

1. Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. J Am Med Assoc 2011;306:2610–1.10.1001/jama.2011.1834Suche in Google Scholar

2. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578–88.10.1056/NEJMoa055227Suche in Google Scholar

3. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–77.10.1056/NEJMoa060900Suche in Google Scholar

4. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 2005;172:1569–73.10.1503/cmaj.045055Suche in Google Scholar

5. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–6.10.1056/NEJM199707243370403Suche in Google Scholar

6. Graham IM, Daly L, Refsum H, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1997;277:1775–81.10.1001/jama.1997.03540460039030Suche in Google Scholar

7. Zhou J, Moller J, Ritskes-Hoitinga M, Larsen ML, Austin RC, Falk E. Effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atherosclerosis 2003;168:255–62.10.1016/S0021-9150(03)00138-2Suche in Google Scholar

8. Colgan SM, Austin RC. Homocysteinylation of metallothionein impairs intracellular redox homeostasis: the enemy within! Arterioscler Thromb Vasc Biol 2007;27:8–11.10.1161/01.ATV.0000254151.00086.26Suche in Google Scholar

9. Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011;58:1025–33.10.1016/j.jacc.2011.05.028Suche in Google Scholar

10. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378:584–94.10.1016/S0140-6736(11)60872-6Suche in Google Scholar

11. Rimm EB, Stampfer MJ. Folate and cardiovascular disease: one size does not fit all. Lancet 2011;378:544–6.10.1016/S0140-6736(11)61057-XSuche in Google Scholar

12. Herrmann W, Obeid R, Schorr H, Geisel J. The usefulness of holotranscobalamin in predicting vitamin B12 status in different clinical settings. Curr Drug Metab 2005;6:47–53.10.2174/1389200052997384Suche in Google Scholar

13. Andres E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004;171:251–9.10.1503/cmaj.1031155Suche in Google Scholar

14. Spence JD. Nutrition and stroke prevention. Stroke 2006;37:2430–5.10.1161/01.STR.0000236633.40160.eeSuche in Google Scholar

15. Vogiatzoglou A, Oulhaj A, Smith AD, Nurk E, Drevon CA, Ueland PM, et al. Determinants of plasma methylmalonic acid in a large population: implications for assessment of vitamin B12 status. Clin Chem 2009;55:2198–206.10.1373/clinchem.2009.128678Suche in Google Scholar

16. Bang H, Mazumdar M, Spence JD. Tutorial in biostatistics: analyzing associations between total plasma homocysteine and B vitamins using optimal categorization and segmented regression. Neuroepidemiology 2006;27:188–200.10.1159/000096149Suche in Google Scholar

17. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002;50:1789–95.10.1046/j.1532-5415.2002.50506.xSuche in Google Scholar

18. Refsum H, Smith AD. Homocysteine, B vitamins, and cardiovascular disease. N Engl J Med 2006;355:207.Suche in Google Scholar

19. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830–8.10.1016/S1474-4422(07)70219-3Suche in Google Scholar

20. Poli D, Antonucci E, Cecchi E, Marcucci R, Liotta AA, Cellai AP, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 2005;36: 2159–63.10.1161/01.STR.0000183620.06179.7bSuche in Google Scholar PubMed

21. Spence JD, Tamayo A, Lownie SP, Ng WP, Ferguson GG. Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke 2005;36:2373–8.10.1161/01.STR.0000185922.49809.46Suche in Google Scholar PubMed

22. Madani A, Beletsky V, Tamayo A, Munoz C, Spence JD. High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound versus TCD microemboli. Neurology 2011;77:744–50.10.1212/WNL.0b013e31822b0090Suche in Google Scholar

23. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233–40.10.1161/01.CIR.0000163561.90680.1CSuche in Google Scholar

24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–8.10.1161/01.STR.22.8.983Suche in Google Scholar

25. Spence JD. Mechanisms of thrombogenesis in atrial fibrillation. Lancet 2009;373:1006.10.1016/S0140-6736(09)60604-8Suche in Google Scholar

26. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010;170:1622–31.10.1001/archinternmed.2010.348Suche in Google Scholar PubMed

27. Huang T, Chen Y, Yang B, Yang J, Wahlqvist ML, Li D. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr 2012;31:448–54.10.1016/j.clnu.2011.01.003Suche in Google Scholar PubMed

28. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br Med J 2010;341:c6273.10.1136/bmj.c6273Suche in Google Scholar PubMed PubMed Central

29. Alsagaff MY, Thaha M, Aminuddin M, Yogiarto RM, Yogiantoro M, Tomino Y. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J Int Med Res 2012;40:340–9.10.1177/147323001204000135Suche in Google Scholar PubMed

30. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933–8.10.1161/01.CIR.0000085067.55901.89Suche in Google Scholar PubMed

31. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension 2012;59:375–81.10.1161/HYPERTENSIONAHA.111.187310Suche in Google Scholar PubMed PubMed Central

32. van GC, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med 2007;45:1683–7.Suche in Google Scholar

33. Rocha MS, Teerlink T, Janssen MC, Kluijtmans LA, Smulders Y, Jakobs C, et al. Asymmetric dimethylarginine in adults with cystathionine beta-synthase deficiency. Atherosclerosis 2012;222:509–11.10.1016/j.atherosclerosis.2012.03.009Suche in Google Scholar PubMed

34. Rueda-Clausen CF, Cordoba-Porras A, Bedoya G, Silva FA, Zarruk JG, Lopez-Jaramillo P, et al. Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 2012;19:417–25.10.1111/j.1468-1331.2011.03534.xSuche in Google Scholar PubMed

35. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering plasma total homocysteine to prevent recurrent stroke, myocardial infarction, and death in ischemic stroke patients: results of the Vitamin Intervention for Stroke Prevention (VISP) Randomized Trial. J Am Med Assoc 2004;291:565–75.10.1001/jama.291.5.565Suche in Google Scholar PubMed

36. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 1999;18:405–10.10.1159/000013486Suche in Google Scholar PubMed

37. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. J Am Med Assoc 2010;303:1603–9.10.1001/jama.2010.490Suche in Google Scholar PubMed

38. Loscalzo J. Homocysteine trials – clear outcomes for complex reasons. N Engl J Med 2006;354:1629–32.10.1056/NEJMe068060Suche in Google Scholar PubMed

39. Obeid R, Shannan B, Herrmann W. Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging. Med Hypotheses 2011;77:884–8.10.1016/j.mehy.2011.08.002Suche in Google Scholar PubMed

40. Koyama K, Yoshida A, Takeda A, Morozumi K, Fujinami T, Tanaka N. Abnormal cyanide metabolism in uraemic patients. Nephrol Dial Transplant 1997;12:1622–8.10.1093/ndt/12.8.1622Suche in Google Scholar PubMed

41. Wang R. Is H2S a stinky remedy for atherosclerosis? Arterioscler Thromb Vasc Biol 2009;29:156–7.10.1161/ATVBAHA.108.180190Suche in Google Scholar PubMed

42. Koyama K, Ito A, Yamamoto J, Nishio T, Kajikuri J, Dohi Y, et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis 2010;55: 1069–78.10.1053/j.ajkd.2009.12.035Suche in Google Scholar PubMed

43. Hasuike Y, Nakanishi T, Moriguchi R, Otaki Y, Nanami M, Hama Y, et al. Accumulation of cyanide and thiocyanate in haemodialysis patients. Nephrol Dial Transplant 2004;19:1474–9.10.1093/ndt/gfh076Suche in Google Scholar PubMed

44. Perna AF, Luciano MG, Ingrosso S, Pulzella P, Sepe I, Lanza D, et al. Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrol Dial Transplant 2009;24:3756–63.10.1093/ndt/gfp378Suche in Google Scholar PubMed